Using Atorvastatin to Protect Kidneys in Patients with Inflammatory Response Syndrome
Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index
PHASE1 · Minia University · NCT05946122
This study is testing if atorvastatin can help protect the kidneys of patients with systemic inflammatory response syndrome.
Quick facts
| Phase | PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 106 (estimated) |
| Ages | 25 Years to 70 Years |
| Sex | All |
| Sponsor | Minia University (other) |
| Locations | 1 site (Minia, Minia University) |
| Trial ID | NCT05946122 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of atorvastatin, a cholesterol-lowering medication, on renal protection in patients experiencing systemic inflammatory response syndrome (SIRS). The study will involve administering atorvastatin or a placebo to evaluate its impact on renal arterial resistive index, a measure of kidney function. The trial aims to determine if atorvastatin can mitigate kidney damage in this patient population. It is a Phase 1 interventional study, focusing on safety and efficacy.
Who should consider this trial
Good fit: Ideal candidates for this study are male and female patients diagnosed with systemic inflammatory response syndrome.
Not a fit: Patients with hemodynamic instability, chronic kidney disease, intra-vascular coagulopathy, or myopathy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new therapeutic option to protect kidney function in patients suffering from systemic inflammatory response syndrome.
How similar studies have performed: While the specific approach of using atorvastatin for renal protection in SIRS is novel, similar studies have explored statins for various inflammatory conditions with some success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients ( male and female) with systemic inflammatory response ( total leucocytic count \>12,000 mm3'. temperature \>38 C, Heart rate \>90 b/min and respiratory rate\>20 cycle). Exclusion Criteria: * Hemodynamic instability * Pre-admission chronic kidney disease. * Intra-vascular coagulopathy * Patients with myopathy.
Where this trial is running
Minia, Minia University
- Mina Maher Raouf — Minia, Minia University, Egypt (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Renal Protection